Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Petersen, P. M.
Right arrow Articles by Hansen, S. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Petersen, P. M.
Right arrow Articles by Hansen, S. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 10:1475-1483, 1999
© 1999 European Society for Medical Oncology

research-article

The course of long-term toxicity in patients treated with cisplatin-based chemotherapy for non-seminomatous germ-cell cancer

P. M. Petersen1,2, and S. W. Hansen1

1Department of Oncology Finsencenter
2Department of Growth and Reproduction, Copenhagen University Hospital, Rigshospitalet Copenhagen, Denmark

Correspondence to: P. M. Petersen, University Department of Growth and Reproduction, Section GR 5064, Copenhagen University Hospital; Rigshospitalet, 9 Blegdamsvej, 2100 Copenhagen, Denmark

Background: The prognosis of advanced testicular cancer has improved considerably after the introduction of cisplatin-based combination chemotherapy. The improved prognosis of testicular cancer has brought the long-term toxicity of the treatment into focus.

Patients and methods: Long-term toxicity was investigated prospectively intil more than 10 years after after treatment in a group of 22 patients treated with six series of cisplatin based chemotherapy (PVB) for testicular cancer. We have focused on nephro-, neuro-, pulmonary-, and gonadal toxicity.

Results: Glomerular filtration rate (GFR) decreased significantly during treatment but increased during follow-up and all the patients had normal values of GFR 10–15 years after treatment. Carbon monoxide diffusion capacity (TLco) decreased during PVB treatment in smokers. TLco remained unchanged during the first years after PVB treatment, but improvement of TLco was seen in some patients more than 43 months after treatment. Paresthesia was reported by 83% of the patients immidiately after treatment, 50% at follow-up 4–9 years after chemotherapy and 14% prevalence 11–15 hears after treatment. The reported decline in neurotoxicity was verified by normalisation of vibration perception. Gonadal toxicity was severe and persistent although improvement was seen in a few patients even many years after treatment.

Conclusions: The patients treated with PVB were physically and socially well-being at follow-up investigation 11–15 years after treatment. Improvements in pulmonary- and renal function, and recovery from neurotoxicity was seen during the long-term follow-up periode. Gonadal toxicity was severe and persistent.

chemotherapy, cisplatin, long-term toxicity, testicular cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
M. Brydoy, J. Oldenburg, O. Klepp, R. M. Bremnes, E. A. Wist, T. Wentzel-Larsen, E. R. Hauge, O. Dahl, and S. D. Fossa
Observational Study of Prevalence of Long-term Raynaud-Like Phenomena and Neurological Side Effects in Testicular Cancer Survivors
J Natl Cancer Inst, November 25, 2009; (2009) djp413v1.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. S. Haugnes, N. Aass, S. D. Fossa, O. Dahl, M. Brydoy, U. Aasebo, T. Wilsgaard, and R. M. Bremnes
Pulmonary Function in Long-Term Survivors of Testicular Cancer
J. Clin. Oncol., June 10, 2009; 27(17): 2779 - 2786.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
C. O'Flaherty, F. Vaisheva, B.F. Hales, P. Chan, and B. Robaire
Characterization of sperm chromatin quality in testicular cancer and Hodgkin's lymphoma patients prior to chemotherapy
Hum. Reprod., May 1, 2008; 23(5): 1044 - 1052.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. R. Feldman, G. J. Bosl, J. Sheinfeld, and R. J. Motzer
Medical Treatment of Advanced Testicular Cancer
JAMA, February 13, 2008; 299(6): 672 - 684.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
D. J. Vaughn, G. A. Gignac, and A. T. Meadows
Long-Term Medical Care of Testicular Cancer Survivors
Ann Intern Med, March 19, 2002; 136(6): 463 - 470.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. D. Fossa, N. Aass, M. Winderen, O. P. Bormer, and D. R. Olsen
Long-term renal function after treatment for malignant germ-cell tumours
Ann. Onc., February 20, 2002; 13(2): 222 - 228.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.